恶性肿瘤骨转移的治疗选择
Treatment Options for Bone Metastasis of Malignant Tumor
DOI: 10.12677/ACM.2022.123307, PDF,   
作者: 马国洋, 杨德文：内蒙古医科大学，内蒙古 呼和浩特
关键词: 恶性肿瘤；骨转移；治疗；手术；放射治疗；综述；Malignant Tumor； Bone Metastases； Treatment； Surgery； Radiation Therapy； Summary
摘要: 骨转移瘤是骨骼系统中最常见的恶性肿瘤，原发于骨骼系统外的恶性肿瘤通过血行、淋巴等途径转移至骨，使患者产生强烈骨痛、活动受限、病理性骨折、脊髓压迫等症状，严重影响恶性肿瘤患者的生活质量，并增加了发病率和死亡率。目前恶性肿瘤骨转移患者的治疗主要以外科手术，和局部姑息放疗为主，治疗目的主要是缓解患者疼痛症状，提高生活质量。本文主要就恶性肿瘤骨转移的治疗手段及最新进展方面进行探讨，以带来更多的思考。
Abstract: Bone metastases are the most common malignant tumors in the skeletal system. Malignant tumors originating outside the skeletal system metastasize to bone through hematogenous and lymphatic channels, causing severe bone pain, limited activity, pathological fracture, spinal cord compression and other symptoms, seriously affecting the quality of life of patients with malignant tumors, and increasing morbidity and mortality. At present, the treatment of malignant tumor patients with bone metastasis is mainly surgery and local palliative radiotherapy; the main purpose of treatment is to relieve pain symptoms and improve the quality of life. This article mainly discusses the treatment and the latest progress of bone metastasis of malignant tumor, in order to bring more thinking.
文章引用：马国洋, 杨德文. 恶性肿瘤骨转移的治疗选择[J]. 临床医学进展, 2022, 12(3): 2137-2140. https://doi.org/10.12677/ACM.2022.123307

参考文献

[1] Coleman, R.E. (2001) Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies. Cancer Treatment Reviews, 27, 165-176. [Google Scholar] [CrossRef] [PubMed]
[2] Selvaggi, G. and Scagliotti, G.V. (2005) Management of Bone Metastases in Cancer: A Review. Critical Reviews in Oncology/Hematology, 56, 365-378. [Google Scholar] [CrossRef] [PubMed]
[3] Coleman, R.E. (1997) Skeletal Complications of Malignancy. Cancer, 80, 1588-1594. [Google Scholar] [CrossRef] 
[4] 李林, 赵祯, 郭兴. 恶性肿瘤骨转移影像学诊断[J]. 中华核医学杂志, 2006, 26(5): 315-318.
[5] Fili, S., Karalaki, M. and Schaller, B. (2009) Mechanism of Bone Metastasis: The Role of Osteoprotegerin and of the Host-Tissue Microenvironment-Related Survival Factors. Cancer Letters, 283, 10-19. [Google Scholar] [CrossRef] [PubMed]
[6] Shupp, A.B., Kolb, A.D., Mukhopadhyay, D. and Bussard, K.M. (2018) Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. Cancers, 10, 182. [Google Scholar] [CrossRef] [PubMed]
[7] Macedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L. and Goncalves, F. (2017) Bone Metastases: An Overview. Oncology Reviews, 11, 321. [Google Scholar] [CrossRef] [PubMed]
[8] Robinson, R.G., Preston, D.F., Baxter, K.G., Dusing, R.W. and Spicer, J.A. (1993) Clinical Experience with Strontium-89 in Prostatic and Breast Cancer Patients. Seminars in Oncology, 20, 44-48.
[9] Rogers, M.J., Xiong, X., Ji, X., Mönkkönen, J., Russell, R.G., Williamson, M.P., Ebetino, F.H. and Watts, D.J. (1997) Inhibition of Growth of Dictyostelium discoideum Amoebae by Bisphosphonate Drugs Is Dependent on Cellular Uptake. Pharmaceutical Research, 14, 625-630. [Google Scholar] [CrossRef] 
[10] 郝平. 骨转移性肿瘤的非外科治疗选择[J]. 实用肿瘤杂志, 2008, 23(4): 301-303.
[11] Green, J.R. and Rogers, M.J. (2002) Pharmacologic Profile of Zoledronic Acid: A Highly Potent Inhibitor of Bone Resorption. Drug Development Research, 55, 210-224. [Google Scholar] [CrossRef] 
[12] Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O.A., Miladinovic, B., Glasmacher, A., Kumar, A. and Djulbegovic, B. (2010) Bisphosphonates in Multiple Myeloma. The Cochrane Database of Systematic Reviews, 3, CD003188. [Google Scholar] [CrossRef] 
[13] Huang, W.W., Huang, C., Liu, J., Zheng, H.Y. and Lin, L. (2012) Zoledronic Acid as an Adjuvant Therapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 7, e40783. [Google Scholar] [CrossRef] [PubMed]
[14] Steger, G.G. and Bartsch, R. (2011) Denosumab for the Treatment of Bone Metastases in Breast Cancer: Evidence and Opinion. Therapeutic Advances in Medical Oncology, 3, 233-243. [Google Scholar] [CrossRef] [PubMed]

为你推荐